NAMS vs NVS: Which Is the Better Buy in 2026?

Last updated November 2026

Short answer

NVS is the larger of the two ($286.41B market cap): the incumbent the market prices for continued execution (15.27x forward earnings, beta 0.45). NAMS is the smaller challenger ($2.27B), still expected to post a loss next year: more room to run, but more to prove. If you believe in growth, NAMS fits: analysts expect its revenue to rise 21% next year, against 7% for NVS. If you believe in profit, NVS fits: it is expected to make money next year (15.27x forward earnings), while NAMS is still expected to post a loss.

NAMS vs NVS: the tie-breaker metrics

Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

MetricNAMSNVSWhat it tells you
Market cap$2.27B$286.41BSize. The larger name is the incumbent; the smaller has more room to grow and more to prove.
Forward P/E-9.1315.27Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up.
Beta0.140.45Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through.
Price vs 52-week range4% of range58% of rangeWhere today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why.
Price / book3.607.69How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price.

Before you buy: how NAMS and NVS affect your concentration

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. NAMS and NVS share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined NAMS and NVS exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

What does NewAmsterdam Pharma Company (NAMS) do?

NewAmsterdam Pharma Company N.V. is a clinical-stage biopharmaceutical company headquartered in Naarden, the Netherlands, and listed on Nasdaq under the ticker NAMS. Its lead candidate is obicetrapib, an oral, once-daily, low-dose CETP inhibitor being developed as a non-statin option (alone or as a fixed-dose combination with ezetimibe) to lower LDL cholesterol in patients who are not reaching targets on existing therapy. The company reported positive topline data from registrational Phase 3 trials including BROADWAY, BROOKLYN and TANDEM, and is running the large PREVAIL cardiovascular outcomes trial; European rights are partnered with the Menarini Group, and on September 21, 2026 the European Commission approved obicetrapib as Ubeslo (10 mg monotherapy) and Evlarco (with 10 mg ezetimibe) for primary hypercholesterolaemia, the drug's first approval worldwide. A Phase 2b trial called SPINOZA, which dosed its first participant in September 2026, now tests obicetrapib in preclinical Alzheimer's disease, building on an earlier Phase 2a program.

Full NAMS guide

What does Novartis AG (NVS) do?

Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. Over the past several years it deliberately reshaped itself into a pure-play innovative-medicines business: it spun off the Alcon eye-care division in 2019 and separated the Sandoz generics and biosimilars unit in 2023, distributing those shares to Novartis holders. What remains is a focused portfolio of patented prescription drugs concentrated in four therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic disease. Oncology is its largest contributor, and the company has built a reputation for high core operating margins, reaching roughly 40% in 2025. Revenue was about $56.7 billion in 2025, roughly 10% above 2024, and trailing twelve-month revenue is about $57.4 billion with net income near $10.0 billion.

Full NVS guide

NAMS vs NVS: how do they differ?

Both fit overlapping themes, but they are not interchangeable. Here is what each one depends on.

  • NAMS drivers: Obicetrapib approval path; Oral, once-daily convenience versus injectables.
  • NVS drivers: Priority growth brands offsetting the cliff; Focused, high-margin innovative-medicines model.

Which fits which kind of investor

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The company is still essentially pre-revenue, with about $26 million of trailing revenue, much of it one-time Menarini milestones, against a trailing net loss of about $205 million, so the valuation depends on obicetrapib being approved in the US and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis. For NVS, the dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed.

NAMS or NVS: which should you pick?

If the story you believe is NAMS's (Obicetrapib approval path), NAMS is the more direct way to own it; if it is NVS's (Priority growth brands offsetting the cliff), NVS is. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the NAMS and NVS guides.

NAMS vs NVS: the full fundamentals

NAMS. The revenue base is small and lumpy, consisting mainly of milestone and supply income under the Menarini agreement, so traditional multiples are not meaningful. At about $2.3 billion, the market cap is roughly 3.5 times the cash balance, down from about $4.4 billion in May, as the EU approval was overshadowed by doubts about the PREVAIL interim. Analysts expect about $34.6 million of revenue in 2026 and $42.0 million in 2027, with losses continuing, and 14 analysts carry a mean target near $51.

NVS. At about $152, NVS trades near 29 times trailing earnings but only about 15 times forward estimates, a gap that widened after a third quarter in which reported profit fell to about $1.2 billion while core EPS beat. Analysts expect EPS of about $9.07 in 2026 and $9.93 in 2027. The analyst mean target of roughly $157 sits close to the current price, so how fast the growth brands keep absorbing the generic erosion, and the run of pipeline readouts into 2027, matter more than any single trailing figure. Figures are approximate and tied to the asOf date; verify live numbers before acting.

Headline figures (approximate, November 2026): NAMS shows revenue (ttm) ~$26M; Q3 2026 ~$19.2M, mostly Menarini milestones, net loss (ttm) ~$205M; Q3 2026 ~$17.4M (incl. ~$23.1M warrant gain), eps (q3 2026) ~-$0.12 vs ~-$0.44 expected, cash ~$643M cash and securities, negligible debt; NVS shows revenue (ttm) ~$57.4B; Q3 2026 revenue ~$15.03B, up ~5% year over year, growth drivers Priority brands Kisqali, Kesimpta, Pluvicto, Leqvio, and Scemblix offsetting Entresto's generic decline, margins (ttm) ~75% gross, ~34% operating, ~17.5% net, net income (ttm) ~$10.0B.

The bottom line: NAMS vs NVS

NAMS and NVS are related but distinct: same themes, different businesses and risks. Neither wins in the abstract, and whichever you pick is worth sizing so one theme does not take over your portfolio. Walnut can show your combined NAMS and NVS exposure against your real portfolio. It is not an investment adviser.

Wondering how NAMS or NVS fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about NewAmsterdam Pharma Company

Ask Walnut's AI anything about NAMS and see how it fits what you own.

FAQ

What is the difference between NAMS and NVS?

+

NewAmsterdam Pharma Company N.V. Novartis AG is a Swiss pharmaceutical company, and NVS is its US-listed American Depositary Receipt trading on the NYSE. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.

Is NAMS or NVS the better stock?

+

Neither is universally better. NVS is the larger incumbent; NAMS is the smaller challenger. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.

Which is cheaper, NAMS or NVS?

+

A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.

Should you own both NAMS and NVS?

+

Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.

What are the risks of NAMS vs NVS?

+

NAMS: The company is still essentially pre-revenue, with about $26 million of trailing revenue, much of it one-time Menarini milestones, against a trailing net loss of about $205 million, so the valuation depends on obicetrapib being approved in the US and commercially adopted; a regulatory setback or a disappointing PREVAIL outcomes result would remove much of the thesis. The near-term risk is sharper now: RBC's statistical work puts the chance of a positive PREVAIL interim in early 2027 at 35% to 38%, and an interim that falls short would at minimum push the outcomes story out to the final analysis. CETP inhibitors as a class have a difficult history, with several prior candidates from large pharma failing in outcomes trials, which keeps skepticism elevated. Concentration is extreme because essentially all value sits in one molecule. Ongoing losses mean future capital raises and shareholder dilution are possible despite the current cash cushion of about $643 million. Commercial risk is real even after approval, given entrenched generics, injectable PCSK9 competitors, and payer access hurdles, and the stock's roughly 46% drop in 2026 shows how quickly sentiment can move. Third-quarter revenue also flattered the run rate: analysts expect only about $1.2 million of revenue in the first quarter of 2027 once milestone payments fall away, and the narrower Q3 loss leaned on a non-cash warrant gain. NVS: The dominant risk is the patent cliff: Entresto, Tasigna, and Promacta/Revolade are losing exclusivity, and Entresto alone was the largest seller, so the priority growth brands must scale fast enough to fill the gap, which is not guaranteed. Analysts expect 2026 EPS to be about flat before rising about 10% in 2027, and reported earnings fell about 69% year over year in the latest quarter. Pipeline risk is structural because late-stage trials can fail and regulators can reject or delay approvals, turning expected future revenue into a write-off, as pelacarsen's failed HORIZON outcomes trial did in 2026. Large acquisitions such as Avidity add integration and financing risk and raised debt, which stood at about $48 billion against about $8.9 billion of cash at September 30, 2026. US drug-pricing policy, potential pharmaceutical tariffs, and pricing pressure are outside the company's control and could compress margins, and in November 2026 the CEO warned that US limits on investment in Chinese biotech could hurt drug development. Because NVS is a Swiss ADR, US investors also carry dollar-versus-Swiss-franc currency risk, and Swiss dividend withholding tax reduces net income for some holders. Concentration in a handful of growth drugs means a single clinical or commercial setback can move the stock.

Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell NAMS or NVS; figures are approximate and dated (as of November 2026). Verify current data before investing.